Complicated Urinary Tract Infections Therapeutics
1. Blujepa patent expiration
Treatment: Treatment of female adult and pediatric patients 12 years of age and older weighing at least 40 kg with uncomplicated urinary tract infections
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8389524 | GLAXOSMITHKLINE | Tricyclic nitrogen containing compounds as antibacterial agents |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 25, 2030 |
| Generating Antibiotic Incentives Now(GAIN) | Mar 25, 2035 |
Drugs and Companies using GEPOTIDACIN MESYLATE ingredient
NCE-1 date: 25 March, 2034
Market Authorisation Date: 25 March, 2025
Dosage: TABLET
More Information on Dosage
BLUJEPA family patents
2. Doribax patent expiration
Treatment: Method of treating bacterial infections
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8247402 | SHIONOGI INC | Crystal form of pyrrolidylthiocarbapenem derivative |
Mar, 2021
(4 years ago) | |
| US5317016 | SHIONOGI INC | Pyrrolidylthiocarbapenem derivative |
Jun, 2015
(10 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 12, 2012 |
Drugs and Companies using DORIPENEM ingredient
NCE-1 date: 13 October, 2011
Market Authorisation Date: 05 October, 2010
Dosage: INJECTABLE
How can I launch a generic of DORIBAX before it's drug patent expiration?
More Information on Dosage
DORIBAX family patents
3. Fetroja patent
expiration
Treatment: Method of treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp) comprising administering cefiderocol sulfate tosylate
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9238657 | SHIONOGI INC | Cephalosporin having catechol group |
Nov, 2033
(7 years from now) | |
| US10004750 | SHIONOGI INC | Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof |
Sep, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9949982 | SHIONOGI INC | Preparation containing cephalosporin having a catechol moiety |
Sep, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-844) | Sep 25, 2023 |
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Nov 14, 2029 |
Drugs and Companies using CEFIDEROCOL SULFATE TOSYLATE ingredient
NCE-1 date: 14 November, 2028
Market Authorisation Date: 14 November, 2019
Dosage: POWDER
More Information on Dosage
FETROJA family patents
4. Invanz patent expiration
Treatment: Treatment of bacterial infectious disease
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5478820 (Pediatric) | MSD SUB MERCK | Antibiotic compounds |
May, 2016
(9 years ago) | |
| US5652233 | MSD SUB MERCK | Antibiotic compounds |
Feb, 2013
(12 years ago) | |
|
US5952323 (Pediatric) | MSD SUB MERCK | Carbapenem antibiotic |
Nov, 2017
(8 years ago) | |
| US7342005 | MSD SUB MERCK | Antibiotic compounds |
Feb, 2013
(12 years ago) | |
|
US7342005 (Pediatric) | MSD SUB MERCK | Antibiotic compounds |
Aug, 2013
(12 years ago) | |
|
US5652233 (Pediatric) | MSD SUB MERCK | Antibiotic compounds |
Aug, 2013
(12 years ago) | |
| US5478820 | MSD SUB MERCK | Antibiotic compounds |
Nov, 2015
(10 years ago) | |
| US5952323 | MSD SUB MERCK | Carbapenem antibiotic |
May, 2017
(8 years ago) | |
Drugs and Companies using ERTAPENEM SODIUM ingredient
Market Authorisation Date: 21 November, 2001
Dosage: INJECTABLE
How can I launch a generic of INVANZ before it's drug patent expiration?
More Information on Dosage
INVANZ family patents
5. Zemdri patent expiration
Treatment: Method of using plazomicin to treat bacterial infections
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8383596 | CIPLA USA | Antibacterial aminoglycoside analogs |
Jun, 2031
(5 years from now) | |
| US9688711 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9266919 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(2 years from now) | |
| US8822424 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 25, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 25, 2028 |
Drugs and Companies using PLAZOMICIN SULFATE ingredient
NCE-1 date: 26 June, 2027
Market Authorisation Date: 25 June, 2018
Dosage: SOLUTION
More Information on Dosage
ZEMDRI family patents